tbuckley/cabot-search huggingface dataset:
Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Dai Chihara, Mohamed Amin Ahmed, Yasuhiro Oki, Jason R Westin, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Hun Ju Lee, Francesco Turturro, Felipe Samaniego, Sattva S. Neelapu, Alma Rodriguez, Nathan Fowler, Michael Wang, Luis E. Fayad, Richard Eric Davis, Loretta Nastoupil
Journal: Blood (2015)
TLR4-NF-κB activation inducing colon cancer biological diversity related with different APC genotypes.
Authors: Yongsheng Wang, Feng Wen
Journal: Journal of Clinical Oncology (2015)

e14698 Background: Previous investigations have shown TLRs/NF-κB activation related with contrary biological effects in colon cancer. APC gene mutation is frequent events in carcinogenesis of colon cancer. Here we investigate the function and cross-talk mechanism of TLRs/ NF-κB pathway activation and APC/GSK-3β/β-catenin though NF-κB and β-catenin, which related with cell growth and apoptosis. Methods: APC was knocked down in human colon cancer cell line HCT116 and human normal colon cell line NCM460 with lenti-viral packaging system. Different APC status cell lines were stimulated with LPS (lipopolysaccharide, TLR4 agonist). The molecular events from two pathway were investigated. Results: Thecell proliferation was promotedboth in HCT116-SiAPC and HCT116-ShAPC treated with LPS, while that was inhibited in HCT116 cells. The activation of TLRs/NF-κB signaling pathway by LPS was regulated with APC/GSK-3β/β-catenin pathway differently in cells with different APC status and ultimately influenced cells apoptosis. In vivo experiments showed that LPS promoted HCT116-ShAPC tumor growth while inhabited tumor growth of HCT116, the difference of which was significant (P < 0.05). The related molecular events were confirmed in tumor tissue. Conclusions: In summary, changes of APC phenotype produced different biological behavior by regulating the levels of β-catenin, which interacted with NF-κB in activated TLR4-NF-κB pathway. Our study also suggests that it is important of APC genotype for targeting TLR4-NF-κB pathway in prevention or therapy of colon cancer.
CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
Authors: Peter Martin, Sin-Ho Jung, Jeffrey L. Johnson, Brandy Pitcher, Rebecca L. Elstrom, Nancy Bartlett, Kristie A. Blum, Kristy L. Richards, John Leonard, Bruce D. Cheson
Journal: Journal of Clinical Oncology (2014)

8521 Background: The CALGB 50401 randomized phase II trial demonstrated the safety and efficacy of lenalidomide plus rituximab in (pts) with previously treated follicular lymphoma (FL). CALGB 50803 was a multicenter phase II trial of lenalidomide plus rituximab in pts with previously untreated FL. Methods: Pts with grade 1-3a FL, stage 3-4 or bulky stage 2 (> 7 cm), FLIPI 0-2, and no prior systemic therapy were eligible to receive rituximab 375 mg/m2 weekly x 4 during cycle 1 and day 1 of cycles 4, 6, 8, and 10, plus lenalidomide 20 mg on days 1-21 for a total of twelve 28-day cycles. Restaging was performed on weeks 10, 24, and 52, then q4 months for 2 years, and q6 months until progression for up to 10 years. The primary objective was to evaluate complete response (CR) rate based on 2007 IWG criteria. Results: From October 2010 to September 2011, 65 subjects were enrolled. Median age was 53 years; 34 were female; 14 had bulky disease; 20 were FLIPI 0-1, 41 FLIPI 2, 2 FLIPI 3; and 2 had insufficient data. Fifty pts completed 12 cycles of lenalidomide. Reasons for discontinuation included refusal/withdrawal (N=6), adverse events (N=4), progression (N=2), and extended treatment delay (N=1). Grade 3-4 hematologic toxicity included neutropenia (19%), lymphopenia (8%), and thrombocytopenia (2%). Febrile neutropenia occurred in 1 pt. Grade 3-4 non-hematologic toxicity occurring in at least 2 pts included rash (8%), infection (8%), pain (8%), fatigue (6%), tumor lysis (3%). The overall RR in evaluable subjects was 93% (53/57); the CR rate was 72%. There was no significant association between CR rate and FLIPI risk, histological grade, or bulky disease. The median time to CR was 10 weeks and 92% of PET-negative CRs occurred by 24 weeks. With a median follow-up of 2.3 years, the 2-year PFS is 89%. Conclusions: Lenalidomide plus rituximab was well tolerated and effective in pts with untreated FL. These data are similar to those reported with chemotherapy-based therapy and support evaluation of this regimen in randomized trials. Clinical trial information: NCT01145495.
Advanced Prostate Cancer and Postoperative Radiotherapy
Authors: David L Sherr
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.
Authors: G. H. Mickisch, B. Schwander, B. J. Escudier, J. Bellmunt, J. P. Maroto, C. Porta, S. Walzer, M. Nuijten
Journal: Journal of Clinical Oncology (2010)

4612 Background: There are currently three licensed first-line metastatic renal cell carcinoma (mRCC) targeted therapies, allowing the therapy of a broad first-line mRCC population with good or intermediate prognosis: the vascular endothelial growth factor inhibitor bevacizumab (BEV) given in combination with interferon-alpha-2a (IFN), and the tyrosine kinase inhibitors (TKI) sunitinib (SUN) and pazopanib (PAZ). All have shown significant increase in progression-free survival (PFS) in first-line mRCC therapy. These targeted therapies are currently competing to be primary choice; hence, in the absence of direct head-to-head comparison, there is a need for valid indirect comparison assessment. Methods: Gold-standard indirect comparison methods were applied to PFS data of the pivotal phase III trials. As BEV+IFN and SUN have been compared to IFN, indirect comparison was enabled by the common IFN comparator arms: The independent central review PFS hazard ratios (HR) for BEV+IFN vs. IFN (0.57) and for SUN vs. IFN (0.54) have been used for the analysis. As PAZ was compared to placebo (PLA) a connector trial (IFN vs. PLA) is required for the indirect comparison. The PFS HR for PAZ vs. PLA (0.40) was applied through an indirect step comparing PLA vs. IFN. Sensitivity analyses taking into account real-life influence of patient compliance on clinical outcomes were performed. Results: The indirect efficacy comparison resulted in a statistically non-significant PFS difference of BEV+IFN vs. SUN (HR: 1.06; 95%CI: 0.77-1.46; p=0.71) and of BEV+IFN vs. PAZ (range based on different connector trials; HR: 0.82-1.13; p=0.48-0.88). Simulating real-life patient compliance and its effectiveness impact showed a strengthened trend towards BEV+IFN without reaching statistical significance. Conclusions: There is no statistically significant PFS difference between BEV+IFN and TKIs in first-line mRCC. These findings imply that additional treatment decision criteria such as tolerability and therapy sequencing need to be considered to guide treatment decisions. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche, GlaxoSmithKline, Novartis, Pfizer Roche AstraZeneca, Bayer, GlaxoSmithKline, Novartis, Pfizer, Roche, Takeda, sanofi-aventis Bayer, Bayer, Novartis, Novartis
Richard Shayle Bartholomew
Authors: Brian W Fleck, Calbert I Phillips, Mark Wright
Journal: BMJ (2016)

Richard Shayle Bartholomew (“Shayle”) was born in Plymouth. His early education took place at Kelly College, Tavistock, Devon. He studied medicine at Queens’ College, Cambridge, and London’s Middlesex Hospital.

Shayle worked at Witwatersrand University, Johannesburg, South Africa, from 1967 to 1971. He undertook epidemiology research into …
Likely Sexual Transmission of Zika Virus from a Man with No Symptoms of Infection — Maryland, 2016
Authors: Richard B. Brooks, Maria Paz Carlos, Robert A. Myers, Mary Grace White, Tanya Bobo-Lenoci, Debra Aplan, David Blythe, Katherine A. Feldman
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In June 2016, the Maryland Department of Health and Mental Hygiene (DHMH) was notified of a nonpregnant woman who sought treatment for a subjective fever and an itchy rash, which was described as maculopapular by her provider. Laboratory testing at the Maryland DHMH Laboratories Administration confirmed Zika virus infection. Case investigation revealed that the woman had not traveled to a region with ongoing transmission of Zika virus, but did have sexual contact with a male partner who had recently traveled to the Dominican Republic. The male partner reported exposure to mosquitoes while traveling, but no symptoms consistent with Zika virus infection either before or after returning to the United States. The woman reported no other sex partners during the 14 days before onset of her symptoms and no receipt of blood products or organ transplants.
Case 11-1962
Authors: Farahe Maloof
Journal: New England Journal of Medicine (1962)

Presentation of CaseA sixty-one-year-old Italian chef was referred to the hospital because of gangrene of the lower extremities.One month previously he was admitted to another hospital after suddenly collapsing at home. Physical examination revealed a moderately severe right hemiplegia and aphasia. The liver edge was palpable 4 fingerbreadths below the right costal margin. The cephalin flocculation was negative in forty-eight hours; the thymol turbidity was 6.75 units. A lumbar puncture yielded clear, acellular cerebrospinal fluid with an initial pressure of 180 mm.; the protein was 43 mg. per 100 ml. A left carotid arteriogram was normal. Anticoagulant therapy . . .
CT-guided radiofrequency ablation in the management of pulmonary colorectal metastases.
Authors: E. N. Petre, X. Jia, C. T. Sofocleous, R. H. Thornton, W. Alago, N. E. Kemeny, S. B. Solomon
Journal: Journal of Clinical Oncology (2011)

e17526 Background: Radiofrequency ablation (RFA) has emerged as an effective treatment of unresectable lung metastases that preserves pulmonary function. Methods: Forty-eight patients with unresectable colorectal pulmonary metastases underwent CT-guided RFA from December 2004 to May 2010. A baseline post treatment scan was obtained 4-6 weeks after RFA to document technique effectiveness defined as coverage of the tumor by encircling ground glass opacity. Follow-up imaging studies were compared every 3 months thereafter to evaluate the RFA site for local tumor progression. The primary end points were time to first local progression for tumors and overall survival for patients, determined from the time of the RFA. Kaplan-Meier methodology was used to analyze these endpoints. A Cox proportional hazard model with robust inference was used to estimate the associations between baseline factors and survival endpoints, accounting for correlations between lesions from the same patients. Results: Seventy-one lesions were ablated in 48 patients. Tumor size ranged from 0.4 to 3.5 cm. The median number of metastases ablated per patient was 1 (range, 1 – 3). Median follow-up was 16 months. Median survival from the time of RFA was 35.4 months (95% CI 23.1 – 47.3 months). One-, 2- and 3-year overall survival rates were 95% (95% CI 0.83-0.99), 69% (95% CI 0.49-0.83) and 49% (95% CI 0.49-0.83), respectively. Eleven of 71 lesions progressed. Median time to progression was not reached. One-, 2- and 3-year local tumor progression-free survival rates were 89% (95% CI 0.78-0.95), 75% (95% CI 0.57-0.86), and 75% (95% CI 0.57-0.86), respectively. Among the progressed lesions, five of them were retreated, with only one lesion having a second progression. Size was only marginally associated with lesion progression (HR=0.93, P value=0.07) in this cohort. There was no periprocedural mortality. Pneumothorax requiring chest tube placement developed in 14 of the total 67 sessions (21%). Conclusions: Radiofrequency ablation is an effective minimally invasive technique that preserves lung function and has very good local control rates in patients with colorectal pulmonary metastases, with 75 % progression free survival at 3 years.
Keratin-dependent thymic stromal lymphopoietin expression suggests a link between skin blistering and atopic disease
Authors: Vinod Kumar, Matthias Behr, Dimitra Kiritsi, Andrea Scheffschick, Anja Grahnert, Melanie Homberg, Agnes Schwieger-Briel, Thilo Jakob, Leena Bruckner-Tuderman, Thomas M. Magin
Journal: Journal of Allergy and Clinical Immunology (2016)
A retrospective analysis of the consequences of acid suppressive therapy (AST) on ketoconazole (K) efficacy in advanced androgen-independent prostate cancer (AIPC).
Authors: S. V. Keisner, S. Shah, G. W. Jean, S. M. GressettUssery, J. Dowell
Journal: Journal of Clinical Oncology (2010)

e15114 Background: The area under the curve (AUC) of K has been shown to be decreased by 83.4% and 95% when administered concurrently with omeprazole and ranitidine, respectively. No published studies have examined the clinical impact of concurrent K and AST in patients with AIPC. Methods: This study evaluated patients with AIPC treated with K between January 1, 1999 and September 30, 2009. Patients included in the analysis had failed androgen deprivation therapy and were subsequently initiated on K. Patients receiving AST other than histamine-2 antagonists or proton pump inhibitors and those without baseline or subsequent prostate specific antigen (PSA) values were excluded. The primary objective was to evaluate PSA response (PSA decline ≥50% maintained at least 4 weeks) in patients receiving K with (group 1)(G1) or without (group 2)(G2) concurrent AST. Results: A total of 30 patients (G1 – 11 pts; G2 – 19 pts) were included in the analysis. Mean age in G1 and G2 was 71.8 and 69.6 years, respectively. Most patients had received prior therapy with an antiandrogen (91.0% G1 and 100% G2) and fewer patients received antiandrogen withdrawal therapy (27.3% G1 and 21.1% G2). Median baseline PSA was 109.4 ng/ml (G1) and 86.9 ng/ml (G2) (p=0.55). Median duration of K was 7.23 months in G1 and 5.83 months in G2 (p=0.09). Compliance with K was 81.8% (G1) and 100% (G2). Median duration of concurrent AST was 3.83 months (range 2.0-20.4 months) in G2. PSA response and time to PSA response were statistically similar between G1 and G2 (72.7% and 47.4%; p=0.26 and 1.2 vs. 0.9 months; p=0.53). Median progression free survival (PFS) was higher in G2 (11.5 vs. 6.9 months; p=0.047). Conclusions: Use of concurrent AST and K in pts with AIPC did not decrease PSA response rate, but PFS was unexpectedly increased. Larger studies are needed to verify these results. No significant financial relationships to disclose.
Reply to Kadayifci et al.
Authors: Hirotoshi Ishiwatari, Hiroshi Kawakami, Hiroyuki Hisai, Kei Yane, Manabu Onodera, Kazunori Eto, Shin Haba, Toshinori Okuda, Hideyuki Ihara, Takehiro Kukitsu, Ryusuke Matsumoto, Keisuke Kitaoka, Tomoko Sonoda, Tsuyoshi Hayashi
Journal: Endoscopy (2016)

We appreciate the comments made by Dr. Kadayifci regarding our study in which we concluded that complete endoscopic treatment with a single catheter is more likely when choosing a balloon catheter over a basket catheter for the extraction of bile duct stones ≤ 10 mm [1].
The Difficulty of Predicting Long-term Weight Loss After Gastric Bypass
Authors: Amy Neville
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
A Smartphone Application to Deliver a Treat-to-Target Insulin Titration Algorithm in Insulin-Naive Patients With Type 2 Diabetes: A Pilot Randomized Controlled Trial
Authors: Yong Mong Bee, Ada Portia M. Batcagan-Abueg, Choy-Lye Chei, Young Kyung Do, Benjamin Haaland, Su-Yen Goh, Phong Ching Lee, Priscilla Pei Sze Chiam, Emily Tse Lin Ho, David B. Matchar
Journal: Diabetes Care (2016)

An emerging trend in telemedicine has been the development of health applications (apps) for smartphones. Apps focusing on insulin dose calculators are widely available, but the majority of them may contribute to incorrect dose recommendations that put patients at risk for overdose or hypoglycemic events (1). Published data evaluating the effectiveness of using an app in purposely guiding insulin dose titration among patients with type 2 diabetes mellitus (T2DM) is scarce.

In this pilot study, we developed a smartphone app called “Diabetes Pal” and investigated its feasibility to deliver an insulin titration algorithm in insulin-naive T2DM patients. A 24-week, randomized, open-label, parallel-group trial was conducted at the Singapore General Hospital between March 2013 and March 2015. The study was approved by the ethics board of the Singapore Health Services and registered with ClinicalTrials.gov (NCT01950676).

Insulin-naive T2DM patients with suboptimal glycemic control (HbA1c ≥7.5% [58 mmol/mol]) despite use of two or more oral glucose-lowering drugs were recruited and randomized in a 1:1 ratio into the intervention and control groups. The randomization list was computer generated with a fixed block size of four within each of five endocrinologists. Treatment allocation codes were concealed in sequentially numbered envelopes that were opened each time a patient was enrolled. Participants received a one-time individual educational session with a diabetes nurse educator. Participants were instructed to start with 10 units of insulin detemir at bedtime, self-monitor fasting blood glucose (FBG) daily, and self-titrate insulin every 3 days using a prescribed algorithm to reach a target FBG of 72–126 mg/dL (4.0–7.0 mmol/L). The algorithm was based on the mean FBG (mFBG) over 3 days; +4 when mFBG exceeded 180 mg/dL (10 mmol/L) and +2 when mFBG was 126–180 mg/dL (7.0–10.0 mmol/L). If FBG was <72 mg/dL (<4.0 mmol/L), the dose was …
Overweight, Obesity, and All-Cause Mortality
Authors: Swapna Abhyankar, Clement J. McDonald
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer.
Authors: S. Mukherjee, C. Hurt, G. Griffiths, T. Crosby, J. Staffurth, S. Bridges, J. A. Bridgewater, A. Mcdonald, S. Falk, T. S. Maughan
Journal: Journal of Clinical Oncology (2010)

TPS222 Background: Around 7,400 patients are diagnosed with pancreatic cancer in the UK each year and mortality from the disease parallels its incidence, indicating that an effective treatment is required. Localized inoperable cancer accounts for 30-40% of advanced disease and its optimal management is unclear. Chemotherapy alone is the predominant modality in the UK while CRT is the treatment of choice in the USA. It has been reported that participants receiving either modality have a median survival in the region of 10 months. Nonrandomized studies have shown that selected participants who attain stable or responsive disease after 3 to 4 months of induction chemotherapy may benefit from consolidation CRT. Both gemcitabine and capecitabine have been shown to be potential radiosensitisers. Methods: The Cancer Research UK funded National Cancer Research Institute SCALOP trial is a two-arm randomized phase II trial using a Fleming's single stage design for each arm. Patients will receive 16 weeks of GEMCAP induction chemotherapy; 76 of those who have responded, or have stable disease, will then be randomised to receive 5.5 weeks of either gemcitabine- or capecitabine-based consolidation chemoradiation (50.4 Gy in 28 fractions with either gemcitabine 300 mg/m2 weekly or capecitabine 830mg/m2 bd ). The trial will assess: 1) What are the activity, toxicity, and feasibility of use of the regimens and does either justify consideration as an arm in a future phase III trial? 2) Is it possible to deliver high quality CRT across centres in the UK? 3) In participants who progress following induction chemotherapy, what is the pattern of care in UK centres and what is their prognosis? The trial incorporates a radiotherapy quality assurance element consisting of a radiotherapy protocol, a test case that must be successfully completed before recruitment can begin at a centre, and ongoing assessment of all plans for compliance with protocol. The trial will also store blood samples for future translational studies. The trial has just opened to recruitment in 5 centers in the UK with 23 further centers in set up. No significant financial relationships to disclose.